Johnson & Johnson (J&J) is in discussions to purchase Protagonist Therapeutics, a move that would enhance their current collaboration, as reported by The Wall Street Journal (WSJ). While a deal is not certain, the acquisition could significantly increase Protagonist's current market value of more than $4bn. According to FactSet, J&J, which holds 4% of Protagonist's shares, is collaborating with the company on an oral immune disease treatment, targeting conditions such as plaque psoriasis and ulcerative c ...